Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TBNA) is a relatively novel, minimally invasive methodology to sample peribronchial masses with real-time guidance (1,2), widely used all over the world. The most common indications for EBUS are the staging of the mediastinum for suspected non-small cell lung cancer and the diagnosis of unexplained mediastinal lymphadenopathy. Usually EBUS is well tolerated, with very few major contraindications; guidelines suggest that patients who experienced myocardial infarction should wait 6 weeks before the procedure, which is however contraindicated when myocardial ischemia, arrhythmias, severe hypoxemia at rest, coagulation or platelet function disorders are present (1).EBUS-TBNA is less available and more expensive than rigid bronchoscopy (RB) which remains the best choice for extraction of airway foreign bodies, when a flexible scope is not suited or in case of large biopsies. However, the diagnostic power of RB in terms of lung cancer staging or evaluation of peripheral pulmonary lesions is lower compared to EBUS-TBNA (3) in the general population and speculatively in COPD patients.